Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma

Next Previous
Trial Profile

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrutinib (Primary) ; Antifungals; Cytarabine; Dexamethasone; Doxorubicin liposomal; Etoposide; Isavuconazole; Methotrexate; Rituximab; Temozolomide
  • Indications CNS cancer; Diffuse large B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 08 Jul 2025 Planned primary completion date changed from 15 Jun 2025 to 15 Jun 2026.
  • 24 Feb 2025 Status changed from suspended to recruiting.
  • 29 Jan 2025 Status changed from recruiting to suspended due to on administrative hold pending an amendment.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top